Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies by Igoe, N et al.
  
 
Design of a biased potent small molecule inhibitor of the bromodomain and PHD finger-
containing (BRPF) proteins suitable for cellular and in vivo studies  
 
Niall Igoe,
a
 Elliott D. Bayle,
a
 Oleg Fedorov,
b
 Cynthia Tallant,
b
 Pavel Saitsky,
b
 Catherine Rogers,
b
 
Dafydd R. Owen,
c
 Gauri Deb,
d
 Tim C. P. Somervaille,
 d
 David M. Andrews,
e
 Neil Jones,
f
 Anne 
Cheasty,
f
 Hamish Ryder,
f
 Paul E. Brennan,
b
 Susanne Müller,
b,g
 Stefan Knapp,
b,g,h 
 and Paul V. Fish 
a,
* 
 
a
 UCL School of Pharmacy, 29/39 Brunswick Square, London, WC1N 1AX, UK 
b
 Nuffield Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Old 
Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK 
c
 Pfizer Worldwide Medicinal Chemistry, 610 Main Street, Cambridge, MA 02139, USA 
d
 Leukemia Biology Laboratory, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK 
e
 AstraZeneca Discovery Sciences, Darwin Building, Cambridge Science Park, Cambridge CB4 0FZ, 
UK        
f
 CRT Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 
3AT, UK 
g
 Buchmann Institute for Molecular Life Sciences, Max-von-Laue-Strasse 15, D-60438 Frankfurt am 
Main, DE 
h
 Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Max-von-Laue-Strasse 
9, D-60438 Frankfurt am Main, DE 
 
ABSTRACT: The BRPF (bromodomain and PHD finger-containing) family are scaffolding proteins 
important for the recruitment of histone acetyltransferases of the MYST family to chromatin. 
Evaluation of the BRPF family as a potential drug target is at an early stage although there is an 
emerging understanding of a role in acute myeloid leukemia (AML). We report the optimization of 
  
 
fragment hit 5b to 13-d as a biased, potent inhibitor of the BRD of the BRPFs with excellent selectivity 
over non-class IV BRD proteins. Evaluation of 13-d in a panel of cancer cell lines showed a selective 
inhibition of proliferation of a subset of AML lines. Pharmacokinetic studies established that 13-d had 
properties compatible with oral dosing in mouse models of disease (Fpo 49 %). We propose that NI-42 
(13-d) is a new chemical probe for the BRPFs suitable for cellular and in vivo studies to explore the 
fundamental biology of these proteins.  
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INTRODUCTION 
Bromodomains (BRDs) are protein interaction modules that bind to acetylated lysine containing 
sequence motifs on chromatin and non-chromatin proteins, and act as epigenetic reader domains.
1
 
Despite large sequence variations, bromodomains share a conserved fold with a central deep, largely 
hydrophobic acetyl-lysine (Ac-Lys) binding pocket, which for many family members is considered 
highly druggable.
2
 Accordingly, since the publication of the first bromodomain inhibitors of the 
Bromodomain and extra-terminal (BET) family in 2010,
3,4
 inhibitors for the major branches of the 
bromodomain family tree have been generated.
5
 Importantly, for many of the bromodomains more 
than one inhibitor, from alternative scaffolds are available,
 
providing confidence in the observed 
biological results.
6,7
 In addition, structurally related compounds that don’t bind to the respective 
bromodomain often complement the inhibitor package lending credibility to the observed findings.
3,8,9
 
In human, 61 bromodomains are present in 46 proteins and some exist as alternatively spliced 
forms.
10
 The bromodomain and PHD finger-containing (BRPF) protein family of bromodomains 
contains four members. BRPF1A and BRPF1B are generated by alternative splicing resulting in a 
longer BRPF1A isoform, which has a 6 residue insert in the BRD, and the shorter BRPF1B isoform.
10
 
The related BRPF2 (also termed BRD1) and BRPF3 proteins share the general domain structure with 
BRPF1A and 1B comprising a double PHD and zinc finger arrangement, a bromodomain, and a C-
terminal chromo/Tudor-related PWWP domain. The PWWP domain of BRPF1 binds to trimethylated 
Lys36 in histone H3 (H3K36me3) and is important for targeting BRPF1 to chromatin,
11
 while the BRD 
of BRPF1 recognizes multiple Ac-Lys modifications on the N-terminal histone tail, in particular 
H2AK5ac, H4K12ac, and H3K14ac.
12
 This modular arrangement points to a role of the BRPF family 
members as scaffolding proteins. Indeed, BRPFs are found in a tetrameric complex with ING5 and 
Eaf6/EPC-related scaffold subunit, as well as one of the MYST family members of the H3K9 and 
H3K14 histone acetyl transferases (HATs): MOZ or MORF; or alternatively HBO1 in case of 
BRPF2/3.
13
 Interestingly, BRPF1 can also associate with HBO1 resulting in a switch from the 
commonly preferred substrate H4 to H3.
14
  
 
Chromosomal translocations that involve the MOZ gene are associated with acute myeloid leukemia 
(AML) and overexpression of HOXA9 and HOXA10 was observed in AML patients with MOZ 
fusions.
15
 BRPF1 is a core component of MOZ/MORF HAT complexes with a key role in their 
  
 
assembly and activation,
16
 and facilitates interaction with chromatin. BRPF1 is essential for the proper 
formation of fetal hematopoietic stem cells as well as expression of stem cell genes such as Hoxa9.
17
 
In AML, MOZ is recurrently targeted by chromosomal translocations and the resulting fusion 
oncoproteins (e.g. MOZ-TIF2) form a stable complex with BRPF1 which interacts with, and 
deregulates, HOX gene loci.
18
 Conversely, depletion of BRPF1 decreased the MOZ localisation on 
HOX genes abrogating transformation, and mutant MOZ-TIF2 engineered to lack HAT activity was 
incapable of deregulation of HOX genes or initiating leukemia.
18
 These data indicate that the MOZ-
TIF2/BRPF1 complex upregulates HOX gene expression possibly mediated by MOZ-dependent 
histone acetylation, leading to development of leukemia.
18
  
 
Further evidence supporting BRPF1 as a credible target for AML includes: (1) its expression is 
highest in acute leukemia cell lines versus all other cell line types;
19
 (2) the normal role of BRPF1 is to 
sustain HOX gene expression in development
18
 and misregulated HOX gene expression is critical to 
the pathogenesis of at least 70% of AML, in particular the MLL mutated subtypes and AMLs with 
mutations in NPM1;
20
 (3) BRPF1 has significant homology with AF10 and AF17, two recurrent fusion 
partners of MLL in human AML;
21
 and (4) the complex formed by BRPF1, ING5 and MOZ binds to, 
and acetylates, histone H3 to act as a co-activator of RUNX1, which is another critical transcriptional 
regulator in AML.
22
 
Hence, this emerging body of evidence supports the potential role of BRPF1 in leukemia and 
prompted us to explore AML as a pathfinder cancer disease. Targeting the MYST complex by 
inhibition of BRPF1B provides a potential therapeutic opportunity in AML, although deletion of the 
BRPF1 bromodomain does not prevent the acetylation of histone H3 by the HBO1/BRPF1 complex.
14
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Figure 1: 1,3-Dimethyl benzimidazolones as inhibitors of the bromodomain of the BRPFs. 
 
Contemporaneous studies identified the 1,3-dimethyl benzimidazolone template as binding to the 
BRD of BRPF1
6,7
 and this core has been independently optimised to give three chemical probes as 
either the pan-BRPF BRD inhibitor OF-1 (1),
23
 or as the selective BRPF1 BRD inhibitors PFI-4 (2)
24
 
and GSK5959 (3)
25
 which share a very similar chemical structure (Figure 1). Piperidine 3 has been 
further optimised to the -methyl piperazine analogue GSK6853 (4) which has significantly improved 
solubility, and properties suitable for cellular and in vivo dosing, albeit by ip administration.
26
  The 1,3-
dimethyl benzimidazolone template has also been used to identify selective TRIM24-BRPF1B dual 
inhibitors.
27
 
The use of selective small molecule inhibitors as chemical probes to investigate the relationship 
between the target and disease is significantly enhanced when two structurally orthogonal chemical 
probes are employed. Two different chemotypes which share the same primary pharmacology are 
likely to offer the advantage of a different secondary pharmacology fingerprint profile and so help 
identify any off-target effects in cellular assays.  
Our aims were to discover new small molecule inhibitors of the BRD of the BRPFs to explore the 
fundamental biology of these proteins and then build target validation to underpin new drug discovery 
programs. Ideally these small molecule inhibitors would be suitable for oral dosing in in vivo model of 
disease and have drug-like properties. Here we report 13-d as a new, structurally orthogonal chemical 
probe for the BRPFs suitable for cellular and in vivo studies. 
  
 
RESULTS AND DISCUSSION 
Origin of Quinolin-2-one Hit Series. The starting point was fragment hit N-methylquinolin-2(1H)-one 
(5b) which was originally identified as binding to PCAF (Figure 2).
28
 In fact, quinolin-2-ones 5a and 5b 
have proven to be efficient and versatile fragment hits for a number of BRDs and further optimization 
has identified potent inhibitors and chemical probes for the BETs,
29
 BRD7/9,
30
 and ATAD2.
31
 
However, our analysis of quinolin-2-one 5b showed it to be a more potent inhibitor of BRPF1 (IC50 
4800 nM) when compared to other BRDs which have been investigated (Table 1).  
 
Figure 2: Evolution of N-methylquinolin-2(1H)-ones as BRPF inhibitors 
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Table 1. Inhibition of BRD activity by fragment hit 5b.
a
 
BRD  
 
IC50 (nM) 
 
BRPF1 
BRD9 
PCAF 
BRD4(BD1) 
ATAD2 
 
 
4800 
14,000 
70,000 
73,000 
>100,000 
a
 BROMOscan assay. BRD IC50 values are geometric 
means of two experiments. Differences of <2-fold 
should not be considered significant. 
 
 
Hence 5b was selected as our starting point for several reasons: (1) excellent ‘hit-like’ properties (mw 
159; cLogP 1.3; LE = 0.62; LLE = 4.0) with no obvious reactive groups; (2) evidence that selectivity 
between BRDs could be achieved and, in particular, over BET family member BRD4; (3) chemically 
enabled with sufficient synthetic chemistry precedent to selectively functionalize each position of the 
template to explore and establish SAR to guide optimization; and (4) a co-crystal structure of BRPF1B 
was solved to support compound design.  
We determined the x-ray co-crystal structure of fragment 5b bound to BRPF1B. As predicted, the 
quinolin-2-one scaffold serves as the acetyl-lysine mimetic with the carbonyl forming a hydrogen bond 
to the conserved Asn708 at 2.9 Å and forming a water mediated hydrogen bond with Tyr665 (Figure 
3). The aromatic core is stabilized with the hydrophobic residues at the ZA channel (Val657 and 
P658) and two residues at the lipophilic shelf adjacent to the ZA channel (Ile652 and Phe653). The 
quinolin-2-one fragment was not large enough to induce conformational changes to the binding site 
and to the Phe714 gatekeeper residue when compared with the ligand-free structure of BRPF1B. 
 
  
 
 
 
Figure 3. N-Methylquinolin-2(1H)-one (5b in yellow) co-crystallized with BRPF1B (grey) and solved at 1.5 Å (pdb 
5T4U). A) 2Fo − Fc electron density map contoured at 1.2σ showing the 5b inhibitor bound to BRPF1B. The 
figure shows the map for the fully refined structure. B) Binding site details of the 5b ligand interaction. 
 
Based on the affinity values (IC50) obtained for 5b among these bromodomains (Table 1), we 
superposed structures and aligned sequences (Figure S4) and observe that the binding specificity of 
5b is very sensitive to the nature of the gatekeeper residue, in which a rather bulky and hydrophobic 
residue is favourable. Also, a lipophilic residue at the ZA-loop (Pro658 for BRPF1B) is preferred to 
stabilize and sandwich the fragment at the binding site. The proline side chain is at 3.4 Å distance to 
the aromatic core of the quinolin-2-one, whereas other side chain residues in this position are pointing 
away to the binding site (Glu1014 for ATAD2; Thr50 for BRD9), or disordered side chains (Lys753 for 
PCAF). 
 
Introduction of a 6-NH2 into the quinolin-2-one template gave 6 which retained affinity whilst providing 
a functional group suitable for further elaboration to explore SAR. This 6-NH2 group is positioned 
adjacent to the ‘WPF shelf’ region of the protein which is important for establishing selectivity between 
BRDs; the corresponding sequence in BRPF1 is Asn-Ile-Phe with Phe714 as the ‘gate-keeper’ 
residue. One of the most significant modifications was the introduction of a 3-Me group to give 7 as a 
potent fragment-like lead (BRPF1 IC50 190 nM; mw 188; cLogP 0.95; LE = 0.67; LLE = 5.8). This 
methyl group enhanced affinity by 10-fold which is near to the maximum feasible from a buried Me 
group in an hydrophobic environment as assessed by binding energy calculations.
32
 Using our co-
  
 
crystal structure of BRPF1B with 5b as a model, the 3-Me of 7 was rationalised as projecting towards 
Y707 with the N1-Me fitting into the Me-pocket as employed by the Me groups of the Ac-Lys residues 
of the histone substrates (Figure S5).
33
 Alternatively, the binding of 7 could also be accommodated by 
flipping the template about the C(2)=O axis and swapping the binding orientation of the 3-Me and N1-
Me groups; both orientations would likely stabilize binding for 7 and improve affinity for BRPF1B when 
compared to 5b.  
  
 
Capping the 6-NH2 group of 6 as a phenyl sulfonamide gave 12-a. This modification introduced a 
bend into the molecule which gave the sulfonamide group the opportunity to turn out of the Ac-Lys 
binding pocket and wrap around the ‘gate-keeper’ Phe714. This binding mode would be quite different 
to the linear 5-carboxamides as used in 2 – 4 which project out past Phe714 towards the sidechain of 
Glu661. Preliminary results with the phenyl sulfonamide 12-a were encouraging showing reasonable 
binding affinity for all three BRPFs with a preferred affinity for BRPF1 (IC50 65 nM) whilst retaining 
good physicochemical properties (mw 314; cLogP 2.0; LE 0.46; LLE 5.2). Hence, we selected 12-a as 
the lead for our SAR studies with the aim of improving binding affinity for the BRPFs whilst reducing 
affinity for other BRDs, especially BRD4. 
 
 
 
 
23: PFI-1 
 
All non-BET BRD inhibitors need to demonstrate excellent selectivity over BRD4 because of the 
dominant phenotype of this protein in cellular models of disease due to the central role played in 
many biological pathways. The selection of quinolin-2-one sulfonamide 12-a as our lead meant it was 
necessary for us to monitor selectivity over BRD4 as 12-a shares some structural similarity with PFI-1 
(23) a chemical probe for the BETs
34
 which is a potent inhibitor of BRD4(BD1 and BD2) (IC50 44 nM) 
and yet has weak BRPF1 affinity (IC50 1800 nM).
29,35
 We aimed to identify a prototype compound with 
a 1000-fold selectivity window for BRPF1 over BRD4 and a BRD4 affinity of IC50 > 5 M to be used in 
cellular phenotypical assays at reasonable concentrations, and then adjust selectivity if required. 
  
 
These criteria are far more stringent than the usual minimum selectivity requirements for chemical 
probes (30-fold)
8,36
 but necessary to deliver a compound that would be ‘fit-for-purpose’ without an 
undercurrent of BRD4 activity to potentially confound biological results.   
Chemistry. The general method for the synthesis of the quinolin-2(1H)-one sulfonamides 12-16 is 
outlined in Scheme 1. The 6-amino quinolin-2(1H)-ones 6-10 were reacted with the appropriate 
sulfonyl chlorides 11 in the presence of base to give the corresponding sulfonamides 12-16. The 
amines 6-10 were prepared by published methods or the application of known procedures. The 
sulfonyl chlorides 11 were purchased from commercial sources or prepared by standard methods. 
Scheme 1: General synthesis of sulfonamides 12-16 
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As the project developed, the need for larger amounts of material to support SAR studies prompted 
the development of an improved synthesis of 6-amino-1,3-dimethylquinolin-2(1H)-one (7)
37,38
  
(Scheme 2). This 5-step sequence was performed on multi-gram scale and represents a high-
yielding, chromatography-free and operationally simple synthesis of 7. 3-Methylquinoline (17) was 
converted to the corresponding 3-methylquinolin-2(1H)-one (18) by the two-step process of oxidation 
with mCPBA to the intermediate N-oxide followed by rearrangement and hydrolysis of the activated 
benzoyl ester with aq. NaOH. Selective N-methylation of 18 was achieved with NaH and MeI in DMF 
to give 19, and nitration with KNO3 in conc. H2SO4 gave 20 in high yield. Finally, reduction of the 6-
NO2 group was most conveniently achieved by catalytic hydrogenation to give amine 7.  
Scheme 2: Synthesis of 6-amino-1,3-dimethylquinolin-2(1H)-one (7) and 13-d. 
 
  
 
 
Reagents and Conditions: (a) mCPBA (1.1 eq), CH2Cl2, 0 
o
C → rt, o/n; (b) C6H5COCl (1.2 eq), aq. 
NaOH (1.0 M), CH2Cl2, 0 
o
C → rt, o/n, 59 % over two steps; (c) NaH (1.1 eq), MeI (1.3 eq), DMF, 0 
o
C 
→ rt, 5 h, 95 %; (d) conc. H2SO4, KNO3 (1.05 eq), 0-5 
o
C → rt, 4 h, 87 %; (e) H2 (1 atmos), Pd/C (5 
wt%, 0.05 eq), EtOH, rt, 7 h, 95 %; (f) 4-cyanobenzenesulfonyl chloride (1.0 eq), pyridine (2.0 eq), 
DMF, rt, o/n, 37-61 %. 
 
The general method for the small-scale synthesis of sulfonamide test compounds 12-16 (typically 20-
100 mg) was to react the amine with an excess of sulfonyl chloride (1.5 eq.) with pyridine (2.0 eq.) in 
CH2Cl2 or DMF at room temperature overnight, followed by evaporation of solvents and direct 
purification of the crude reaction mixture by chromatography. For larger amounts of material, the 
amine was coupled with the sulfonyl chloride (1.0 eq.) with DABCO (2.0 eq.) as the base in DMF at 
room temperature for 6 h. The reaction mixture was poured into ice-cold dilute aqueous HCl; the 
sulfonamide usually precipitated from solution and was collected by filtration.   
Screening Strategy. Compounds were tested for BRPFs BRD binding (∆Tm) with a differential 
scanning fluorimetry (DSF) assay (Table 2). Selected compounds were then screened for inhibition 
(IC50) of BRPF BRD activity as measured by the BROMOscan biochemical assay (Table 3). BRD9 
and BRD4(BD1) were routinely used as BRD counter screens to establish evidence of selectivity in 
both the DSF and BROMOscan assays. Preferred compounds were then evaluated for selectivity 
against a panel of 48 BRDs by DSF and inhibition of BRPF BRD activity was confirmed by 
independent evaluation by an AlphaScreen biochemical assay (IC50). Finally, equilibrium dissociation 
constants (KD) were determined by isothermal titration calorimetry (ITC).  
  
 
Structure Activity Relationships. The SARs were initially focused on exploring substituents on the 
phenyl ring of 12 and then modification of the groups at the N1 and C3 positions of the quinolin-2-one 
core 13-15 (Tables 2 and 3). Furthermore, target compounds were designed to have molecular and 
physicochemical properties consistent with drug-like space. Modulation of the lipophilicity of target 
compounds was achieved by the application of the lighter halogens (F, Cl), small alkyls (Me, Et), 
alkoxy (OMe) and nitriles (CN). 
In general, there was a good correlation between the DSF and BROMOscan data for these 
compounds with very similar trends in ranked order of affinities. However, as has been noted by 
others, the BROMOscan data routinely showed higher affinities when compared to other quantified 
endpoints such as the AlphaScreen or ITC measurements. 
A more complete analysis of phenyl derivative 12-a established some modest selectivity over both 
BRD9 and BRD4(BD1). Introduction of a nitrile at each of the positions of the phenyl ring showed a 
preference for the 3- and 4- positions, 12-c and 12-d respectively, with the 2-CN 12-b being poorly 
tolerated. Combining a 4-CN group with a second substituent at either the 2- or 3-positions on the 
phenyl ring (12-e,f,g,h) offered no significant advantage except for the 2-Me,4-CN analogue 12-f. The 
3-Cl,4-Cl compound 12-h had similar potency to 12-d but at the expense of increased lipophilicity 
(∆cLogP +1.5) and was not pursued .  
As had been seen previously with 6 and 7, once again, a significant improvement in BRPF1 affinity 
was achieved by the introduction of a 3-Me group on the quinolin-2-one of 12-d to give 13-d as the 
most potent compound so far (BRPF1 IC50 7.9 nM; mw 353; cLogP 2.5; LE = 0.45; LLE = 5.6). 
Additional screening of 13-d showed reasonable binding affinity for all three BRPFs with good 
selectivity over BRD9 (39-fold) and BRD4(BD1) (>500-fold)(Figure S2). The introduction of a 2-MeO 
group 13-i also gave a potent inhibitor of BRPF1 activity but, not surprisingly, reintroduced some 
unwanted BRD4 activity.
29
 Compound 13-i represents our closest structural analogue to 23 and yet 
13-i still shows reasonable selectivity over BRD4(BD1) (60-fold). This selectivity can be attributed to a 
combination of the intrinsic preference of the quinolin-2-one core 5b for BRPF1 (Table 1) and the 
accommodation of the substituent at N1. Limited SARs would suggest that BRD4 prefers a N1-H 
whereas BRPF1 prefers a N1-Me; this single point change in chemical structure may represent a 
simple way to switch between BRPF1 and BRD4 activity.  
  
 
Increasing the size of the 3-alkyl substituent from 3-Me to 3-Et (14-d) was poorly tolerated whereas 
exchanging the N1-Me for an N1-Et (15-d) showed similar affinity. Although these simple 
modifications at C3 and N1 of the quinolin-2-one failed to improve the BRPF1 affinity (cf 13-d v 14-d v 
15-d), they did provide some evidence of how the affinity could be reduced to identify an inactive 
close analogue of 13-d (vide infra).  
Preliminary attempts to design a BRPF1 selective inhibitor in the quinolin-2-one template were based 
upon hybrid structures of 13-d with 2. The incorporation of a 6-benzamide and 7-pyrrolidine gave 21 
(Table 3) which proved to be a modest inhibitor of BRPF1 (IC50 220 nM; mw 391; cLogP 3.0; LE = 
0.32; LLE = 3.7) with only an incremental improvement of selectivity over BRD1 when compared to 
13-d (11- vs 6-fold resp.). However, amide 21 had similar potency for BRD9 (IC50 420 nM) and may 
be considered as a modest BRPF1-BRD9 dual inhibitor for further optimization.    
Around this time, our initial efforts to determine the binding mode of a representative quinolin-2-one 
sulfonamide to BRPF1B was achieved by the determination of a co-crystal X-structure of BRPF1B 
with 1,4-dimethylquinolin-2-one 22 (BRPF1 IC50 60 nM; Table 3; Figures 4 and S6). 
 
 
 
Figure 4. Co-crystal structure of 22 (NI-48; reference 38) with BRPF1B bromodomain solved at 1.65 Å (pdb 
5T4V). A) Surface representation B) Cartoon representation of the binding site details of 22 (yellow) bound to 
BRPF1B (grey) and overlaid with ligand-free BRPF1B structure (blue). 
  
 
Compound 22 occupies part of the substrate acetylated peptide-binding groove of the BRD in good 
shape complementarity (Figure 4A). The quinolin-2-one scaffold maintains the same conformation as 
shown for the complex structure with fragment 5b. However, new features of the binding mode arose 
with this novel structure. Interestingly, upon binding, the ligand induces a conformational twist of the 
Phe714 gatekeeper residue. The phenyl side chain forms a parallel, face-centered - stacking 
interaction with the quinolinone core ring at approximately 3.6 Å. Moreover, the new rotamer is 
pointing towards the benzonitrile ring forming a perpendicular T-shaped C-H- interaction. This is 
shown with the structural superposition of the free-ligand BRPF1B structure (Figure 4B). We also 
observe the nitrile group accommodated to a pre-formed hydrophobic cleft with residue Ile713 at the 
top of the C helix. Additional points of interest are that the network of five conserved water 
molecules in the binding pocket is not altered and the NH group from the sulfonamide is stabilized 
through an intra-hydrogen bond to the 7-OMe group on the quinolin-2-one (Figure S6). 
 
  
  
 
Table 2: Evaluation of N-methylquinolin-2(1H)-ones 12-15 in DSF ∆Tm shift assay 
 
12-15 
 
Compound 
 
R
1
 
 
R
3
 
 
X 
 
∆Tm shift at 10 M (
o
C)
 
 
 BRPF1 BRPF2 
(BRD1) 
BRPF3 BRD9 BRD4(BD1) 
         
12-a Me H H 5.3 1.9 1.5 3.5 1.1 
12-b Me H 2-CN 2.4 0.9  2.9 1.3 
12-c Me H 3-CN 4.4 2.1  2.5 1.1 
12-d Me H 4-CN 5.2 2.4  2.3 1.4 
12-e Me H 2-F; 4-CN 3.6 1.3 1.2   
12-f Me H 2-Me; 4-CN 6.5 3.4 2.4 2.2 0.4 
12-g Me H 3-Cl; 4-CN 4.3     
12-h Me H 3-Cl; 4-Cl 4.9 2.5    
         
13-d Me Me 4-CN 9.7 5.1 4.5 3.5 0.95 
         
14-d Me Et 4-CN 5.6 3.3    
         
15-d Et Me 4-CN 5.2 1.5 1.2   
         
         
 
  
 
Table 3: Evaluation of N-methylquinolin-2(1H)-ones 12-15, 21 and 22 in the BROMOscan assay
 a
 
 
 
 
 
12-15 21 22 
           
 
Compound 
 
R
1
 
 
R
3
 
 
X 
 
IC50 (nM) 
 BRPF1 BRPF2 
(BRD1) 
BRPF3 BRD9 BRD4(BD1) 
 
         
12-a Me H H 65 1400 7600 2200 1700 
12-b Me H 2-CN 430 1700    
12-c Me H 3-CN 56 270    
12-d Me H 4-CN 43 200 1000 910 2800 
12-g Me H 3-Cl; 4-CN 62 450 2300 2500 7200 
12-h Me H 3-Cl; 4-Cl 44 230    
         
13-d Me Me 4-CN 7.9
b
 48 260 310 4500 
13-i Me Me 2-OMe 9 130   600 
         
14-d Me Et 4-CN 180     
         
15-d Et Me 4-CN 15     
         
21    220 2600 12000 420 4600 
         
22    60
b
 1800 9300 890 17000 
 
 
a
 BRD IC50 values are geometric means of two experiments (n =2). Differences of <2-fold should not be considered significant. 
b
 n = 4.
  
 
Selectivity of 13-d. Completing the evaluation of lead compound 13-d against all members of the 
class IV family of BRDs in the BROMOscan assay identified affinity for BRD7 but was completely 
selective over the ATAD2s (Table 4). 13-d was confirmed as a potent inhibitor of BRPF1 by 
independent evaluation in an AlphaScreen biochemical assay and with a very similar relative rank 
order of activities to other screening formats (Table 4). 
 
Compound 13-d was then evaluated in a number of assays to establish the broader pharmacological 
selectivity. 13-d was screened for BRD binding by DSF against a panel of 48 BRDs and showed 
excellent selectivity. All activity was confined to the class IV family of BRDs with ∆Tm < 1 
o
C 
stabilization for all non-class IV BRDs (Figure 5; Table S1). ITC data showed that 13-d bound the 
BRD of BRPF1 with an equilibrium dissociation constant, KD, of 40 nM and an enthalpy change, H, of 
-11.7 kcal mol
-1
 (Table 4; Figure 6). Additional ITC studies showed 13-d bound the BRD of BRD1 with 
a KD of 210 nM, whereas binding to BRPF3 and BRD9 was weaker (Table 4; Figure S3).  
 
Compound 13-d has reasonable aqueous solubility and good cell permeability as measured by transit 
performance in the Caco2 cell line but with some evidence of efflux (Table 4). Any cardiovascular risk 
through direct interaction with cardiac ion channels was low as 13-d showed minimal activity against a 
panel of 8 cardiac ion channels in the Eurofins CardiacProfile with only 45.6% normalized inhibition of 
the hERG current amplitudes at 30 μM (Table S2).  
 
Hence, 13-d is a biased, potent inhibitor of the BRD of the BRPFs with excellent selectivity over non-
class IV BRD proteins.  
 
  
 
 
Figure 5. Selectivity profile of 13-d assessed against 48 BRDs (bold type) by thermal shift, ∆Tm (
o
C), 
at 10 M as measured by DSF.  
  
  
 
Table 4: Summary of physicochemical properties, in vitro 
bromodomain inhibition, ITC screening and cell transit 
permeability of 13-d. 
 
 
13-d: NI-42 
Physicochemical properties 
mw      353 
clogP      2.5 
tPSA (Å
2
)     90 
 
Bromodomain inhibition 
BRPF1/2/3   BROMOscan IC50 (nM) 7.9; 48; 260 
BRD7/9  BROMOscan IC50 (nM) 82; 310 
ATAD2A/2B BROMOscan IC50 (nM) >100,000; >100,000 
BRD4(1) BROMOscan IC50 (nM) 4500 
 
BRPF1/2/3   AlphaScreen  IC50 (nM) 140; 760; 2000 
BRD9    AlphaScreen  IC50 (nM) 1100 
BRD4(1) AlphaScreen  IC50 (nM) >20,000 
 
Bromodomain ITC  screening 
BRPF1/2/3  ITC   KD (nM)  40; 210; 940 
BRD9   ITC   KD (nM)  1130 
 
Solubility and cell permeability 
Aqueous solubility    moderate (100 M min)
a
 
Caco2 transit AB/BA, Papp (x10
-6
 cms
-1
)  10/50  
 
 
a
 Maximum concentration used in screening assays created by serial dilution of a 100 mM stock solution of 13-d in DMSO. 
 
  
  
 
Figure 6: ITC data for 13-d with BRPF1. 
 
The figure shows raw binding heats for each 
injection (upper panel) as well as normalized 
binding enthalpies and a non-linear least squares 
fit to a single binding site model. The fit revealed 
KD = 40 nM, H = -11.7 kcal mol
-1
 and TS =         
-1.87 kcal mol
-1
. 
 
 
 
  
  
 
BRPF1B target engagement. Target engagement in living cells was demonstrated in a fluorescence 
recovery after photobleaching (FRAP) assay
39
 using a fusion protein of green fluorescent protein with 
a triplicated BRD of BRPF1B linked to a nuclear localization signal ectopically expressed in the 
human osteosarcoma cell line U2OS. The histone deacetylase (HDAC) inhibitor SAHA was used to 
increase overall levels of histone acetylation resulting in a sufficient window measuring differences in 
recovery time and demonstrating the acetylation dependence of the FRAP experiments. Compound 
13-d displaced BRPF1B-BRDx3 from chromatin at 1 µM as shown by the significantly reduced 
recovery time of the BRPF1B-GFP fusion protein (Figure S7). Hence, these FRAP experiments 
confirm 13-d inhibits BRPF1B BRDs in the nucleus. 
 
AML cell based activity. Compound 13-d has been evaluated in a number of cellular models in order 
to explore a credible link between the BRPF proteins and disease. These cellular models include 
osteoclastogenesis, inflammation and fibrosis; results from these studies will be reported separately. 
Our own interest was to explore the potential role of BRPF1 in acute myeloid leukemia (AML) and 
other cancers.  
  
Table 5. Examples of inhibition of proliferation of AML and other cancer cell lines (GI50) by 13-d. 
Cancer cell line 
a
 
 
GI50 (M) 
AML cell lines: 
OCI-AML2 
Nomo-1 
THP-1 
KG-1 
MV-4-11 
 
Non-AML cell lines: 
SW48, NUGC-4, HepG2, COLO 205, OCUM-1, HUP-T4, LOVO, 
C-99, 22Rv1, SK-CO-1, MOLP-8, OGP-1, AGS, Hs 766t, SNU-5, 
SW948, RKO, OCI-LY-19, KG-1, Panc02.03, SW403, HCC1187, 
NCI-H1437, IM-9, AsPC-1, SW620, LS180 
 
~100 cell lines 
 
 
1.3 
4.6 
5.7 
7.0 
9.9 
 
 
1 - 10 
 
 
 
 
> 30 
a 
AstaZeneca CLIMB panel includes 211 cancer cell lines. 72 h proliferation assay; 9 point dose-response-
curve with a highest concentration of 10 or 30 M (n = 2). For an example of the use of oncology cell panels 
in mechanistic and pathways analysis, see reference 40. 
We treated an indexed cell panel of 211 cancer cell lines (CLIMB panel)
40
 with 13-d for 72 h and 
observed modest and selective inhibition of proliferation of certain AML cell lines (Table 5). Three of 
these lines (NOMO-1, THP-1 and MV-4-11) exhibit translocations targeting MLL. All five lines either 
  
 
originate from patients who presented with AML with significant monocytic lineage differentiation at 
diagnosis (OCI-AML2, NOMO-1, THP-1 and MV-4-11) or have strong latent monocyte/macrophage 
lineage differentiation potential (KG-1), in response, for example, to phorbol ester.
41
 Given the original 
observation of BPRF1-associated MOZ fusions in myelomonocytic leukaemia,
42
 therapeutic targeting 
of BRPF1 may, in particular, be valuable in the myelomonocytic morphologic subtype of human AML.  
Taken together, these results provide clear evidence that 13-d is active in cellular assays although 
additional studies will be required to more fully establish the role of 13-d and the BRPFs in AML. 
Pharmacokinetics. Pharmacokinetic data for 13-d was generated in vivo in mouse (Tables 6 and 
S3A). Following single intravenous administration of 13-d, clearance was low relative to liver blood 
flow and volume of distribution was moderate resulting in an elimination half-life of 2.0 h. Single oral 
administration of 13-d as a suspension showed good oral bioavailability of 49 % even with incomplete 
absorption. These results established that 13-d had pharmacokinetic properties compatible with oral 
dosing in mouse PK-PD models of disease with a 3 mg/kg p.o. dose achieving free drug levels above 
the BRPF1 KD (ITC) for 4-5 h (Table S3B).  
 
Table 6: Mouse pharmacokinetic data for 13-d 
a
  
Liver microsomes, Clint (L/min/mg) 14 
Plasma protein binding, fu   0.03 
 
Intravenous dose (mg/kg)  1.0 
Elimination half-life, T1/2 (h)  2.0 
Blood clearance, Cl (mL/min/kg)  4 
Volume of distribution, Vd (L/kg)  0.7 
 
Oral dose (mg/kg)   3.0 
Cmax (M)    4.0 
Tmax (h)     1.0 
AUC0-∞ (ng.h/mL)   5700 
Bioavailability, Fpo (%)   49 
Fraction absorbed (%)   51 
 
a
 Female CD-1 mouse (n=3) 
  
  
 
Inactive Control. Chemical probes are most valuable when they are partnered with an inactive 
control to assist with the interpretation of phenotypic assays. Ideally, the inactive control will share a 
similar chemical structure and physicochemical properties as close as possible to the active 
compound. Hence we designed a series of close analogues of 13-d where the key recognition 
interactions between the quinolone C2-carbonyl with Asn708 and the Tyr665 water network could be 
disrupted by increasing the size of the alkyl groups flanking the carbonyl and so prevent binding. 
Incorporation of ethyl groups at both N1 and C3 gave 16-d (cf 14-d and 15-d) which removed activity 
as measured against the BRPFs and a representative set of bromodomains in the BROMOscan 
(>100 M) and AlphaScreen assays (>20 M) (Table 7). 
 
  
16d 
mw 381; clogP 3.5; tPSA 90 
 
Table 7. Inhibition (IC50) of BRD activity for inactive control 16-d. 
 IC50 (nM) BRDs 
 
BROMOscan
 a
 
 
 
 
AlphaScreen 
 
> 100,000 
 
77,000 
 
> 20,000 
BRPF1, BRD1, BRPF3, BRD9, BRD7, ATAD2A, ATAD2B, 
BRD4(BD1), CREBBP, PCAF, BAZ2A, TRIM33, CECR2 
SMARCA2A 
 
BRPF1, BRD9, BRD4(BD1), CECR2, FALZ, TAF1A 
a
 BRD IC50 values are geometric means of two experiments (n =2).   
  
 
CONCLUSIONS  
We have designed and evaluated a number of new quinolin-2-one derivatives as inhibitors of BRPF 
BRD activity. Starting with the fragment hit N-methylquinolin-2-one (5b), which had modest affinity for 
PCAF, we demonstrated that 5b had much higher affinity for BRPF1. The preferred binding of 5b to 
BRPF1 was rationalized through an X-ray co-crystal structure determination which underpinned future 
inhibitor design. Optimization of 5b by incorporation of a 6-phenyl sulfonamide gave 12-a and 
preliminary results were encouraging showing reasonable binding affinity for all three BRPFs. SARs 
established that potent BRPF1 inhibition could be retained through incorporation of various groups on 
the phenyl ring of the sulfonamide with a 4-CN group preferred (12-d). A significant improvement in 
affinity was achieved by the introduction of a 3-Me group onto the quinolin-2-one of 12-d to give 13-d 
as the most potent compound prepared whilst retaining good physicochemical properties.  
Compound 13-d was then evaluated in a number of assays to establish the broader pharmacological 
selectivity. 13-d was screened by DSF against a panel of 48 BRDs and showed excellent selectivity 
with all activity confined to the class IV family of BRDs. ITC data showed that 13-d preferentially 
bound the BRD of BRPF1 and BRD1 whereas binding to BRPF3 and BRD9 was weaker. Based on 
these results, 13-d was identified as a biased, potent inhibitor of the BRD of the BRPFs with excellent 
selectivity over non-class IV BRD proteins. BRPF1 target engagement in living cells was 
demonstrated in a FRAP assay. Compound 13-d displaced BRPF1B-BRDx3 from chromatin at 1 µM 
as shown by the significantly reduced recovery time of the BRPF1B-GFP fusion protein.  
Evaluation of 13-d in a panel of cancer cell lines, including AML lines, showed a modest (GI50 1-10 
M) and selective inhibition of proliferation of certain lines, particularly those lines exhibiting 
monocytic lineage differentiation.  These results provide clear evidence that 13-d is active in cellular 
assays. However, additional studies will be required to fully establish the role of 13-d and the BRPFs 
in AML.  
Pharmacokinetic data for 13-d was generated in vivo in mouse with single oral administration of 13-d 
as a suspension showing good oral bioavailability. These results established that 13-d had 
pharmacokinetic properties compatible with oral dosing in mouse PK-PD models of disease with a 3 
mg/kg p.o. dose achieving free drug levels above the BRPF1 KD for 4-5 h.  
  
 
In conclusion, we propose that 13-d is a new, structurally orthogonal chemical probe for the BRPFs 
suitable for cellular and in vivo studies to explore the fundamental biology of these proteins. Chemical 
probe 13-d (NI-42)
38
 will be of most value in the interpretation of phenotypic assays when used in 
conjunction with the inactive control 16-d and with other available chemical probes of the class IV 
BRDs. 
   
  
 
EXPERIMENTAL SECTION 
 
Chemistry methods and compound characterization data for 13-d and 16-d. 
General Methods:  
All anhydrous solvents and reagents were obtained from commercial suppliers and used without 
further purification. Flash chromatography refers to medium pressure silica gel (C60 (40-60 μm)) 
column chromatography, unless otherwise stated. The progress of reactions was monitored by thin 
layer chromatography (TLC) performed on Keiselgel 60 F254 (Merck) silica plates and visualised by 
exposure to UV light at 254 nm. 
Melting points (mp) were determined in open capillary tubes on a Stuart SMP10 apparatus and are 
uncorrected. Infrared (IR) analysis was performed on a Perkin Elmer Spectrum 1000 FT-IR in the 
4000-400 cm
-1
 range. 
1
H Nuclear Magnetic Resonance (
1
H NMR) spectra were recorded on a Bruker 
Advance 400 Spectrophotometer at 400 MHz or Bruker Advance 500 Spectrophotometer at 500 MHz. 
Chemical shifts were measured in parts per million (ppm) relative to tetramethylsilane (δ = 0) using 
the following internal references: CDCl3 (δ 7.26), CD3OD (δ 3.32), DMSO-d6 (δ 2.50). Multiplicities in 
1
H NMR spectra are quoted as: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = 
double doublet, ddd = double double doublet. 
13
C Nuclear Magnetic Resonance (
13
C NMR) spectra 
were recorded on a Bruker Advance 500 Spectrophotometer at 125 MHz. Chemical shifts were 
measured in parts per million (ppm) relative to tetramethylsilane (δ = 0) using the following internal 
references: CDCl3 (δ 77.16), CD3OD (δ 49.00), DMSO-d6 (δ 39.52). 2D NMR techniques HSQC, 
HMQC and HMBC were also utilised for the assignment of 
1
H and 
13
C NMR signals. High-resolution 
mass spectra (HRMS) were recorded on a Thermo Navigator mass spectrometer coupled to an HPLC 
instrument using electrospray ionisation (ESI) and time-of-flight (TOF) mass spectrometry. 
Alternatively, HRMS were recorded at the EPSRC UK National Mass Spectrometry Facility (NMSF) at 
Swansea University. Analytical reverse-phase high-performance liquid chromatography (HPLC) was 
carried out on a XSELECT™ CSH™ C-18 column (2.5 μm; 6 x 50 mm). HPLC experiments (system 
A) were performed with gradient conditions: initial fixed composition 5% B to 50% B over 20 min, then 
increased to 95% B over 2 min, held for 2 min at 95% B, then returned to 5% B in 1 min. Total 
duration of gradient run was 25 min. Eluents used were solvent A (H2O with 0.02% TFA) and solvent 
B (MeCN with 0.02% TFA). Flow rate: 1.00 mL/min. 
  
 
Purity of screening compounds 12-15, 21 and 22 was evaluated by NMR spectroscopy and HPLC 
analysis. All compounds had purity ≥ 95 % except 21 which had a purity of 91 % by HPLC. 
6-Amino-1,3-dimethyl-6-quinolin-2-(1H)-one  (7). A 500 mL round bottom flask was charged with 
1,3-dimethyl-6-nitroquinolin-2-(1H)-one (20) (5.00 g, 22.9 mmol, 1.0 eq.) and palladium on carbon (5 
% wt., 2.44 g, 1.45 mmol, 0.05 eq.).  The flask was sealed then evacuated and back-filled with 
nitrogen three times before adding ethanol (300 mL).  The stirred slurry was then re-evacuated until 
the solvent began to bubble and back-filled with nitrogen once more.  A balloon of hydrogen was 
attached to the flask via a syringe fitted with a stop-cock.  The flask was evacuated until the solvent 
began to boil and then back-filled with hydrogen gas five times.  The reaction was then stirred for 
seven hours after which point the complete consumption of starting material was confirmed by TLC.  
At the end of the reaction, the reaction flask was evacuated and back-filled with nitrogen three times, 
filtered through a pad of Celite
®
 onto a glass-sintered funnel. The Celite
®
  pad was further washed 
with ethanol (300 mL) and then the filtrate concentrated under reduced pressure to give 6-amino-1,3-
dimethyl-6-quinolin-2-(1H)-one (7)  (4.10 g, 95 %) as a pale yellow solid that was not purified further. 
1
H NMR (500 MHz, DMSO-d6):  7.55 (s, 1H), 7.21 (d, J = 8.8 Hz, 1H), 6.87 (d, J = 8.8 Hz, 1H), 6.71 
(s, 1H), 5.04 (br. s, 2H), 3.56 (s, 3H) 2.08 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6): δ 160.9, 143.6, 
135.0, 130.5, 128.7, 120.9, 117.7, 115.0, 110.0, 29.2, 17.5. 
4-Cyano-N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (13-d). To a 
solution of 6-amino-1,3-dimethylquinolin-2(1H)-one (7) (188 mg, 1.00 mmol) and pyridine (158 mg, 
2.00 mmol, 2.0 eq.) in DMF (5 mL) was added 4-cyanobenzenesulfonyl chloride (201 mg, 1.00 mmol, 
1.0 eq.) at room temperature and the reaction mixture stirred overnight. The resulting suspension was 
homogenised by addition of DMF (3 mL), concentrated onto Celite
®
 and purified by column 
chromatography (acetone:hexane, gradient elution 30:70 to 60:40) to give 13-d (129 mg, 0.37 mmol, 
37%) as a white solid. m.pt. 279-282 
o
C (acetone-hexane); 
1
H NMR (400 MHz, DMSO-d6): δ  10.52 
(1H, s), 8.06 - 8.00 (2H, m), 7.90 - 7.84 (2H, m), 7.73 (1H, s), 7.41 (1H, d, J = 9.1 Hz), 7.33 (1H, d, J = 
2.5 Hz), 7.23 (1H, dd, J = 9.1, 2.5 Hz), 3.57 (3H, s), 2.09 (3H, d, J = 1.0 Hz); 
13
C NMR (126 MHz, 
DMSO-d6): δ 161.4, 143.3, 136.3, 135.0, 133.5, 130.8, 130.0, 127.4, 123.5, 120.3, 119.9, 117.5, 
115.5, 115.3, 29.4, 17.3; HRMS m/z (ESI
+
) found (M+H)
+
 354.0908, C18H15N3O3S requires (M+H)
+ 
354.0907; HPLC: Retention time (system A): tR= 8.97 min. Purity: >95%. 
  
 
4-Cyano-N-(1,3-diethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide (16-d) was prepared 
according to general procedure as described for 13-d from 6-amino-1,3-diethylquinolin-2(1H)-one (40 
mg, 0.18 mmol) with 4-cyanobenzenesulfonyl chloride to give 16-d (37 mg, 0.09 mmol) as a pale 
yellow solid. 
1
H NMR (500 MHz, DMSO-d6): δ 10.56 (1H, s), 8.04 (2H, d, J = 8.5 Hz), 7.89 (2H, d, J = 
8.5 Hz), 7.68 (1H, s), 7.46 (1H, d, J = 8.8 Hz), 7.41 (1H, d, J = 2.5 Hz), 7.23 (1H, dd, J = 9.1, 2.5 Hz), 
4.22 (2H, q, J = 6.9 Hz), 1.21 - 1.10 (6H, m), [1xCH2 overlaps with DMSO]; 
13
C NMR (126 MHz, 
DMSO-d6): δ 160.5, 143.4, 135.3, 134.9, 133.6, 133.5, 130.7, 127.4, 123.6, 120.7, 120.3, 117.5, 
115.3, 115.2, 36.9, 23.5, 12.7, 12.5; HRMS m/z (ESI
-
) found (M-H)
-
 380.1057, C20H19N3O3S requires 
(M-H)
- 
380.1069; HPLC: Retention time (system A): tR= 10.36 min. Purity: >95%. 
3-Methylquinolin-2-(1H)-one (18). To a stirred solution of 3-methylquinoline (17) (25.0 g, 175 mmol, 
1.0 eq.) in dichloromethane (875 mL) in a 2 litre round bottom flask at 0 °C was added 3-
chloroperbenzoic acid (70 %, 47.3 g, 192 mmol, 1.1 eq.) portionwise over 10 minutes. The resulting 
solution was allowed to warm to room temperature and then stirred overnight. After completion of the 
reaction, the solution was washed with sodium hydroxide (1.0 M, 300 mL) and the aqueous phase 
extracted with dichloromethane (2 x 300 mL). The organic layers were combined, dried over 
anhydrous MgSO4, filtered and the solvent removed under reduced pressure to yield crude 3-
methylquinolone-N-oxide as a white solid, which was used without further purification. 
To a 2 L three-necked round bottom flask fitted with an overhead mechanical stirrer was charged 
crude 3-methylquinolone-N-oxide followed by dichloromethane (430 mL) and aqueous sodium 
hydroxide solution (1.0 M, 400 mL).  The resulting biphasic mixture was cooled to 0 °C and to this was 
added, under rapid agitation, benzoyl chloride (24.4 mL, 210 mmol, 1.2 eq.) dropwise via a side-arm 
pressure equalised dropping funnel. The suspension was stirred overnight and the resulting 
heterogeneous solution was diluted with diethyl ether and stirred rapidly for 15 minutes. The resultant 
precipitate was collected by filtration, washed with diethyl ether (200 mL) and then water (200 mL) 
and dried under vacuum to give 3-methylquinolin-2(1H)-one (18) (16.3 g 59 % over 2 steps). 
1
H NMR 
(400 MHz, DMSO-d6):  11.72 (br. s, 1H), 7.75 (s, 1H), 7.56 (d, J = 7.8 Hz, 1H), 7.41 (t, J = 8.3 Hz, 
1H), 7.29 (d, J = 8.3 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 2.09 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6): δ 
162.4, 137.9, 136.3, 129.8, 129.0, 126.9, 121.6, 119.4, 114.7, 16.5. 
  
 
1,3-Dimethylquinolin-2-(1H)-one (19). To a solution of 3-methylquinolin-2(1H)-one (18) (16.3 g, 103 
mmol, 1.0 eq.) in anhydrous DMF (500 mL) in a 1 litre round bottom flask cooled to 0 °C and under an 
argon atmosphere was added NaH (60 % wt., 4.50 g, 113 mmol, 1.1 eq.) and the reaction mixture 
stirred for 0.5 hours.   Iodomethane (8.3 mL, 133 mmol, 1.3 eq.) was added dropwise via syringe and 
the reaction mixture stirred for 5 hours. Excess sodium hydride was quenched by the addition of water 
(30 mL) and the solvents removed under reduced pressure.  The resultant slurry was taken up in the 
minimum volume of ethyl acetate and poured onto crushed ice (approximately 200 g).  The resultant 
heterogeneous mixture was stirred rapidly for 15 minutes and then the precipitate collected by 
filtration, washed with cold diethyl ether (100 mL) and dried under vacuum to give 1,3-
dimethylquinolin-2-(1H)-one (19) (16.9 g, 95 %) as a white powder. 
1
H NMR (400 MHz, DMSO-d6):  
7.78 (s, 1H), 7.63 (dd, J = 7.8, 1.3 Hz, 1H), 7.58–7.53 (m, 1H), 7.50–7.48 (m, 1H), 7.26–7.22 (m, 1H), 
3.64 (s, 3H) 2.13 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6): δ 161.7, 138.7, 135.5, 129.5, 128.9, 127.7, 
121.8, 120.0, 114.3, 29.3, 16.5. 
1,3-Dimethyl-6-nitroquinolin-2-(1H)-one (20). A 500 mL round bottom flask was charged with 1,3-
dimethylquinolin-2-(1H)-one (19) (16.9 g, 97.5 mmol, 1.0 eq.) and cooled to 0 °C.  Concentrated 
sulfuric acid (120 mL) was added and the reaction mixture stirred for 0.5 hours during which time 
most of the solid dissolved.  To the resultant pale red solution, potassium nitrate (10.4 g, 102.4 mmol, 
1.05 eq.) was added in two portions.  The reaction mixture rapidly turned yellow and was stirred for a 
further 4 hours, after which it was poured onto crushed ice (approximately 400 g) and stirred rapidly 
for 0.5 hours.  The yellow precipitate was collected by filtration onto a sintered-glass funnel and 
washed with water (2 x 250 mL).  Still on the sintered disk, the resultant filter cake was slurried with 
hot ethanol (200 mL) using a glass rod and allowed to stand for 10 minutes.   The solid was collected 
by filtration to give 1,3-dimethyl-6-nitroquinolin-2-(1H)-one (20)  (18.5 g, 87 %) as a pale yellow solid. 
1
H NMR (400 MHz, DMSO-d6):  8.63 (s, 1H), 8.35 (d, J = 8.8 Hz, 1H), 8.03 (s, 1H), 7.7 (d, J = 8.8 Hz, 
1H), 3.71 (s, 3H) 2.16 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6): δ 161.8, 142.9, 141.4, 135.3, 131.2, 
123.9, 123.5, 119.7, 115.7, 30.1, 17.4. 
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ABBREVIATIONS USED 
AML, acute myeloid leukemia; ATAD2, ATPase family, AAA domain containing; BRD4(BD1), 
bromodomain containing protein 4, first bromodomain; BET, bromodomain and extra terminal domain; 
BRD, bromodomain containing protein; BRPF, bromodomain and PHD finger-containing; CLIMB, Cell 
Lines Indexed for Molecular Biology; DABCO, 1,4-diazabicyclo[2.2.2]octane; DSF, differential 
scanning fluorimetry; DMF, N,N-dimethyl formamide; EAF6, EAS1-associated factor 6; EPC, 
enhancer of polycomb; FRAP, fluorescence recovery after photobleaching; HAT, histone acyl 
transferase; HBO1,  histone acetyltransferase binding to ORC 1 (KAT7); HOX, homeotic; ING5, 
inhibitor of growth family, member 5; ITC, isothermal titration calorimetry; LE, ligand efficiency = 1.4(-
log IC50)/number of heavy atoms; LLE, lipophilic ligand efficiency = (-log IC50) - clogP; mCPBA, 3-
chloroperbenzoic acid; MLL, mixed-lineage leukemia; MORF, monocytic leukemia zinc finger protein-
related factor (KAT6B); MOZ, monocytic leukemia zinc finger (KAT6A); NPM1, Nucleophosmin 1; 
  
 
PCAF, P300/CBP-associated factor; PK-PD, pharmacokinetic-pharmacodynamic; PWWP, Pro-Trp-
Trp-Pro; RUNX1, Runt-related transcription factor 1; SAR, structure activity relationship; TIF2, 
transcriptional mediators/intermediary factor 2; TRIM24, tripartite motif containing 24; WPF, Trp-Pro-
Phe. 
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